Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford is to take part in three new government-funded projects designed to help universities collaborate with each other, and with external organisations, to boost research commercialisation.

None

Image courtesy of Shutterstock

Healthy ageing, the internet of things, and commercialisation in the social sciences are the three themes with involvement from Oxford academics. Oxford is leading the programme on healthy ageing, is a partner in the Sheffield University-led internet of things project, and will also participate in the social sciences initiative led by LSE.

The projects are funded via Research England (formerly the Higher Education Funding Council for England) through its Connecting Capability Fund (CCF). This £100m fund supports university collaboration in research commercialisation with the aims of sharing good practice across the higher education sector, forging external technological, industrial and regional partnerships, and helping deliver the government's industrial strategy priorities.

Oxford recently launched its 150th spinout company based on University research. In 2018 alone, six new companies have been formed and more than £150m has been raised in external investment.

Professor Chas Bountra of Oxford's Nuffield Department of Clinical Medicine is leading the healthy ageing programme, titled UK SPINE KE and also involving Birmingham and Dundee universities. Announced last autumn in the first wave of CCF awards, the £4.82m project will establish a UK-wide network across universities, businesses and the NHS focused on improving health in old age.

Find out more (University of Oxford website)

Similar stories

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

AIMday in Women's Health - registration for academics now open

Events Innovation

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Women's Health.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.

New national study of long-term impacts of debilitating lung damage from COVID-19

Coronavirus COVID-19 General Research

A new national study will investigate the long-term effects of lung inflammation and scarring from COVID-19. The study, launched with £2 million of funding from UK Research and Innovation (UKRI), aims to develop treatment strategies and prevent disability.